JW Pharmaceutical Launches New Dyslipidemia Treatment 'Rivaropeno'

Can Be Taken Regardless of Meals

On January 2, JW Pharmaceutical announced the launch of 'Rivaropeno' (active ingredients: pitavastatin and fenofibric acid), a dyslipidemia treatment that can simultaneously manage low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG).

Rivaroxaban. JW Pharmaceutical

Rivaropeno is a hard capsule that combines pitavastatin and fenofibric acid into a single formulation. It can be used to treat adult patients at high risk of coronary heart disease (CHD) whose LDL-C levels are adequately controlled with pitavastatin 2mg monotherapy, but who still have elevated TG levels and low high-density lipoprotein cholesterol (HDL-C) levels.

Among dyslipidemia patients, there are cases of 'mixed dyslipidemia,' where LDL-C is controlled by statin therapy but TG remains high and HDL-C is low. This has created an unmet need for treatment options that can manage both LDL-C and TG simultaneously.

Fenofibric acid, one of the key ingredients in Rivaropeno, is the active metabolite produced when fenofibrate, a fibrate-class lipid-lowering agent, is converted in the body. It helps improve lipid markers such as TG through the PPAR-α pathway, a receptor that regulates lipid metabolism in the liver and other organs.

In addition, due to the formulation characteristics of fenofibric acid, there is minimal difference in absorption depending on food intake, allowing Rivaropeno to be taken regardless of meals and thereby improving medication convenience.

Following the recent launch of 'Rivarohigh,' a triple combination therapy for dyslipidemia and hypertension based on pitavastatin, JW Pharmaceutical plans to expand its pitavastatin-based 'Rivaro Family' lineup with Rivaropeno and broaden treatment options in clinical practice.

A representative from JW Pharmaceutical stated, "Rivaropeno is a combination therapy designed for patients who need to manage both LDL-C and TG, and by incorporating fenofibric acid, it offers improved medication convenience by allowing administration regardless of meals. Moving forward, we will continue to accumulate and share evidence centered on the Rivaro Family to support the treatment of dyslipidemia patients."